1
|
New RRC, Ramanujam S, Chaudhari V, Bogus M, Travers GN, Namjoshi G. Safety and efficacy of an oral insulin (Capsulin) in patients with early-stage type 2 diabetes: A dose-ranging phase 2b study. Diabetes Obes Metab 2023; 25:953-960. [PMID: 36378077 DOI: 10.1111/dom.14922] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Revised: 11/06/2022] [Accepted: 11/07/2022] [Indexed: 11/16/2022]
Abstract
AIM To compare the pharmacodynamic properties of different doses of regular human insulin administered in capsule form twice daily in a randomised twelve-week open-label study. METHODS A total of 100 individuals (48 males, 52 females) with type 2 diabetes on metformin completed the study according to the protocol. The mean (SD) age was 48.5 (6.7) years, body mass index 25.7 (2.8) kg/m2 and HbA1c 8.10% (0.65%). Subjects randomized upon admission were assigned to one of three groups receiving formulated regular insulin at dose levels of 75 iu BD, 150 iu insulin BD, or 300 iu BD, all in enteric-coated capsules. The primary and secondary endpoints were change from baseline in HbA1c and fasting plasma glucose (FPG), respectively. RESULTS The study met its primary clinical endpoint of a decrease in HbA1c of 0.5% or higher (least square mean decrease 0.52%; P = .004, median decrease 0.6%) in the dose group receiving 150 iu BD. In a subset of this population, with starting HbA1c values of 9% to 9.5%, an average decrease of 1.575% was observed. In the total population, least square mean decreases in HbA1c for the 75 and 300 iu BD groups were -0.11% and -0.42%, respectively. Mean change in FPG in the 150 iu BD dose group was -18.8 mg/dl (P = .017) and -14.8 and -2.7 mg/dl for the 75 and 300 iu BD groups, respectively. A decrease of 20% for triglycerides (-40 mg/dl) was observed in the 150 iu BD dose group. No significant increases in body weight were observed, and significant decreases in systolic blood pressure were seen in all groups. No serious treatment-related adverse events were recorded, and no incidence of hypoglycaemia was reported throughout the entire 12-week study period. CONCLUSIONS Capsulin oral insulin administered twice per day at a dose of 150 iu per capsule is safe, with no confirmed treatment-linked hypoglycaemic events, and results in significant decreases from baseline in HbA1c, FPG and triglycerides.
Collapse
Affiliation(s)
- Roger R C New
- Diabetology Limited, c/o The London Bioscience Innovation Centre, London, UK
- Faculty of Science & Technology, Middlesex University, London, UK
| | | | | | - Michal Bogus
- Diabetology Limited, c/o The London Bioscience Innovation Centre, London, UK
| | - Glen N Travers
- Diabetology Limited, c/o The London Bioscience Innovation Centre, London, UK
| | | |
Collapse
|
2
|
Abstract
Peptide aptamers are short amino acid chains that are capable of binding specifically to ligands in the same way as their much larger counterparts, antibodies. Ligands of therapeutic interest that can be targeted are other peptide chains or loops located on the surface of protein receptors (e.g., GCPR), which take part in cell-to-cell communications either directly or via the intermediary of hormones or signalling molecules. To confer on aptamers the same sort of conformational rigidity that characterises an antibody binding site, aptamers are often constructed in the form of cyclic peptides, on the assumption that this will encourage stronger binding interactions than would occur if the aptamers were simply linear chains. However, no formal studies have been conducted to confirm the hypothesis that linear peptides will engage in stronger binding interactions with cyclic peptides than with other linear peptides. In this study, the interaction of a model cyclic decamer with a series of linear peptide constructs was compared with that of a linear peptide with the same sequence, showing that the cyclic configuration does confer benefits by increasing the strength of binding.
Collapse
Affiliation(s)
- Roger R. C. New
- Vaxcine (UK) Limited, London Bioscience Innovation Centre, London NW1 0NH, UK;
- Faculty of Science & Technology, Middlesex University, Hendon, London NW4 4BT, UK
- Correspondence: or
| | - Tam T. T. Bui
- Centre for Biomolecular Spectroscopy and Institute of Pharmaceutical Science, King’s College, London SE1 1UL, UK;
| | - Michal Bogus
- Vaxcine (UK) Limited, London Bioscience Innovation Centre, London NW1 0NH, UK;
| |
Collapse
|
3
|
Moore BD, New RRC, Butcher W, Mahood R, Steward J, Bayliss M, MacLeod C, Bogus M, Williamson ED. Dual route vaccination for plague with emergency use applications. Vaccine 2018; 36:5210-5217. [PMID: 30017148 DOI: 10.1016/j.vaccine.2018.06.039] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2018] [Revised: 06/08/2018] [Accepted: 06/16/2018] [Indexed: 02/04/2023]
Abstract
Here, we report a dual-route vaccination approach for plague, able to induce a rapid response involving systemic and mucosal immunity, whilst also providing ease of use in those resource-poor settings most vulnerable to disease outbreaks. This novel vaccine (VypVaxDuo) comprises the recombinant F1 and V proteins in free association. VypVaxDuo has been designed for administration via a sub-cutaneous priming dose followed by a single oral booster dose and has been demonstrated to induce early onset immunity 14 days after the primary immunisation; full protective efficacy against live organism challenge was achieved in Balb/c mice exposed to 2 × 104 median lethal doses of Yersinia pestis Co92, by the sub-cutaneous route at 25 days after the oral booster immunisation. This dual-route vaccination effectively induced serum IgG and serum and faecal IgA, specific for F1 and V, which constitute two key virulence factors in Y. pestis, and is therefore suitable for further development to prevent bubonic plague and for evaluation in models of pneumonic plague. This is an essential requirement for control of disease outbreaks in areas of the world endemic for plague and is supported further by the observed exceptional stability of the primary vaccine formulation in vialled form under thermostressed conditions (40 °C for 29 weeks, and 40 °C with 75% relative humidity for 6 weeks), meaning no cold chain for storage or distribution is needed. In clinical use, the injected priming dose would be administered on simple rehydration of the dry powder by means of a dual barrel syringe, with the subsequent single booster dose being provided in an enteric-coated capsule suitable for oral self-administration.
Collapse
Affiliation(s)
- B D Moore
- Department of Pure & Applied Chemistry, University of Strathclyde, Glasgow, UK.
| | - R R C New
- Proxima Concepts Ltd, London BioScience Innovation Centre, UK
| | - W Butcher
- Defence Science & Technology Laboratory, Porton Down, Salisbury UK
| | - R Mahood
- Defence Science & Technology Laboratory, Porton Down, Salisbury UK
| | - J Steward
- Defence Science & Technology Laboratory, Porton Down, Salisbury UK
| | - M Bayliss
- Defence Science & Technology Laboratory, Porton Down, Salisbury UK
| | - C MacLeod
- Department of Pure & Applied Chemistry, University of Strathclyde, Glasgow, UK
| | - M Bogus
- Proxima Concepts Ltd, London BioScience Innovation Centre, UK
| | - E D Williamson
- Defence Science & Technology Laboratory, Porton Down, Salisbury UK
| |
Collapse
|
4
|
Andrade GR, New RRC, Sant'Anna OA, Williams NA, Alves RCB, Pimenta DC, Vigerelli H, Melo BS, Rocha LB, Piazza RMF, Mendonça-Previato L, Domingos MO. A universal polysaccharide conjugated vaccine against O111 E. coli. Hum Vaccin Immunother 2014; 10:2864-74. [PMID: 25483465 DOI: 10.4161/21645515.2014.972145] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
E. coli O111 strains are responsible for outbreaks of blood diarrhea and hemolytic uremic syndrome throughout the world. Because of their phenotypic variability, the development of a vaccine against these strains which targets an antigen that is common to all of them is quite a challenge. Previous results have indicated, however, that O111 LPS is such a candidate, but its toxicity makes LPS forbidden for human use. To overcome this problem, O111 polysaccharides were conjugated either to cytochrome C or to EtxB (a recombinant B subunit of LT) as carrier proteins. The O111-cytochrome C conjugate was incorporated in silica SBA-15 nanoparticles and administered subcutaneously in rabbits, while the O111-EtxB conjugate was incorporated in Vaxcine(TM), an oil-based delivery system, and administered orally in mice. The results showed that one year post-vaccination, the conjugate incorporated in silica SBA-15 generated antibodies in rabbits able to inhibit the adhesion of all categories of O111 E. coli to epithelial cells. Importantly, mice immunized orally with the O111-EtxB conjugate in Vaxcine(TM) generated systemic and mucosal humoral responses against all categories of O111 E. coli as well as antibodies able to inhibit the toxic effect of LT in vitro. In summary, the results obtained by using 2 different approaches indicate that a vaccine that targets the O111 antigen has the potential to prevent diarrhea induced by O111 E. coli strains regardless their mechanism of virulence. They also suggest that a conjugated vaccine that uses EtxB as a carrier protein has potential to combat diarrhea induced by ETEC.
Collapse
Key Words
- CT, cholera toxin
- E. coli
- E. coli, Escherichia coli
- EAEC, enteroaggregative E. coli
- EHEC, enterohemorrhagic E. coli
- EPEC, enteropathogenic E. coli
- EtxB, non-toxic B subunit of LT
- HUS, hemolytic uremic syndrome
- LPS, lipopolysaccharide
- LT, heat labile toxin of ETEC
- O111 polysaccharide
- PAGE, polyacrylamide gel electrophoresis
- SBA-15, Santa Barbara Amorphous-15
- SDS, sodium dodecyl sulfate
- STEC, shiga-producing toxins E. coli
- aEPEC, atypical EPEC
- conjugated vaccine
- t-EPEC, typical EPEC
Collapse
|
5
|
Campbell EJ, Wiles MC, New RRC, Charles SA. A New Enzyme Immunoassay for Activation of Platelets by Biomaterials: Reduced Activation by Phosphorylcholine-Coated Surfaces. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-252-229] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTAn enzyme immunoassay has been developed to semi-quantitate the degree of activation of platelets adhering to biomaterials. The method employs a monoclonal mouse anti-GMP-140 antibody. The glycoprotein GMP-140 is contained in alpha granules of resting platelets and is translocated to the outer membrane of platelets during activation via the thrombin-dependent pathway. A polyclonal anti-mouse IgG peroxidase conjugate is then added and platelet activation can be semi-quantitated by use of a suitable substrate, such as OPD.The results obtained by this method compare well with scanning electron microscopy, and are shown to be less prone to the misinterpretation often associated with other conventional assay systems such as the determination of platelet adhesion by detection of ATP.The adhesion and activation of platelets by biomaterials has been compared before and after coating these materials with phosphorylcholine (PC) derivatives. PC, in its form as a headgroup in membrane phosphoglyceride (lecithin) and ceramide (sphingomyelin) is a ubiquitous component of cell membranes, and displays extremely low interaction and binding with plasma proteins such as Factor XII [1,2], complement [2], fibrinogen [3,2], immunoglobulins [2] and albumin [2,4].Using the immunoassay described here activation of platelets is seen to be dramatically reduced after coating surfaces, such as polyethylene, with PC compared with the untreated control. A PCcoated surface should therefore be an ideal starting point for developing tissue-inducing biomaterials. In addition endothelial cells contain GMP-140 in their secretory granules [5]. This would make this assay a potential tool in the investigation of endothelial cell - biomaterial interaction.
Collapse
|
6
|
Domingos MO, Barbaro KC, Tynan W, Penny J, Lewis DJM, New RRC. Influence of sphingomyelin and TNF-α release on lethality and local inflammatory reaction induced by Loxosceles gaucho spider venom in mice. Toxicon 2003; 42:471-9. [PMID: 14529728 DOI: 10.1016/s0041-0101(03)00200-9] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
It is well known that Loxosceles venom induces local dermonecrosis in rabbits, guinea pigs and humans but not in mice, although, depending on the dose, Loxosceles venom can be lethal to mice. In this work we demonstrate that mice injected intradermally in the dorsal area of the back can survive a lethal dose of Loxosceles gaucho venom and also develop an inflammatory reaction (with infiltration of leukocytes shown by histological analysis) at the local injection site when the venom is co-administered with sphingomyelin. It was observed that more venom was retained for a longer period of time at the local injection site when venom was co-administered with sphingomyelin. The presence of exogenous sphingomyelin did not influence significantly the release of TNF-alpha induced by L. gaucho venom. These results suggest that the action of venom on sphingomyelin, producing ceramide phosphate, causes the development of an inflammatory reaction, which in turn traps the venom in the local area for a long period of time and does not allow it to disperse systemically in a dose sufficient to cause death. Our findings also indicate that the size and availability of the local sphingomyelin pool may be important in determining the outcome of Loxosceles envenoming in different mammalian species.
Collapse
Affiliation(s)
- M O Domingos
- St George's Medical School, Division of Infectious Diseases, Cranmer Terrace, London SW 17 ORE, UK.
| | | | | | | | | | | |
Collapse
|
7
|
Domingos MO, Tynan W, Barbaro KC, Penny J, Lewis DJM, New RRC. Effect of Loxosceles gaucho venom on cell morphology and behaviour in vitro in the presence and absence of sphingomyelin. Toxicon 2003; 42:439-45. [PMID: 14505946 DOI: 10.1016/s0041-0101(03)00199-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
This study was performed to investigate whether the toxic effects of Loxosceles gaucho venom on cells might be exerted via stimulators of TNF-alpha release generated by sphingomyelinase D--a major component of the venom. It was demonstrated that L. gaucho venom alone is unable to induce TNF-alpha release by J774A.1 cells, while in the presence of exogenous sphingomyelin it induces a high level of TNF-alpha release which is significantly increased by incubation with non-inactivated serum. Ceramide phosphate also induces TNF-alpha release in J774A.1 cells, but (unlike sphingomyelin/sphingomyelinase) the level of release is not influenced by the presence or otherwise of non-inactivated serum. L. gaucho venom does not induce proliferation of J774A.1 cells and even at high concentrations it does not affect their viability. J774A.1 cells, which prior to venom treatment were elongated and clumped, round up after venom treatment, but, revert to their original morphology after incubation with fresh medium. TNF-alpha resistant MRC-5 cells and TNF-alpha sensitive MCF-7 cells are susceptible to the toxic effect of both L. gaucho venom and ceramide phosphate. The results obtained in this study demonstrate that exogenous sphingomyelin can modulate, in vitro, the release of TNF-alpha induced by L. gaucho venom in mouse macrophages. In addition, the results also indicate that ceramide phosphate and L. gaucho venom are toxic to several different cell types, via a variety of mechanisms, some, but not all, of which may involve TNF-alpha as an intermediary.
Collapse
Affiliation(s)
- M O Domingos
- Division of Infectious Diseases, St George's Medical School, Cranmer Terrace, SW 17 ORE London, UK.
| | | | | | | | | | | |
Collapse
|